Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ATAI Life Sciences N.V. - Common Shares (NQ:ATAI)

3.835 -0.045 (-1.16%)
Streaming Delayed Price Updated: 12:25 PM EDT, Jul 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,650,683
Open 4.000
Bid (Size) 3.830 (19)
Ask (Size) 3.840 (24)
Prev. Close 3.880
Today's Range 3.700 - 4.000
52wk Range 1.030 - 3.910
Shares Outstanding 166,010,476
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Nasdaq Dips 150 Points; US ISM Manufacturing PMI Rises In June
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Intrigued by the market activity in the middle of the day on Tuesday? Uncover the key winners and losers of today's session in our insightful analysis. 
Via Chartmill

Performance

YTD
+139.7%
+139.7%
1 Month
+89.9%
+89.9%
3 Month
+152.3%
+152.3%
6 Month
+152.3%
+152.3%
1 Year
+144.3%
+144.3%

More News

Read More
Mesoblast, Atai Life Sciences, Melco Resorts & Entertainment And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Let's uncover which stocks are experiencing notable gaps during today's session.
Via Chartmill
DOD to Invest $9.8m into Psychedelic Studies Targeting Active-Duty Soldiers
Via Investor Brand Network
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
From FN Media Group LLC
Via GlobeNewswire
Atai Life Sciences And Merger Partner Set Up Psychedelic Depression Therapy With Encouraging Late-Stage Data
Via Benzinga
Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032
Via FinancialNewsMedia
Topics Death
Get insights into the top gainers and losers of Tuesday's pre-market session.
Via Chartmill
atai Life Sciences Announces $50 Million Private Placement Financing
From atai Life Sciences
Via GlobeNewswire
5 Biotech Stocks with Highly Anticipated Pending Results
Via Stocktwits
Topics Intellectual Property
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LNSR, ATAI, ICAD on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
CrowdStrike, Asana And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Via Benzinga
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Atai Life Sciences Stock Rockets On Merger Plans With Beckley Psytech; Retail Traders Eye Every Dip
Via Stocktwits
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences to Participate in Upcoming Investor Conferences
From atai Life Sciences
Via GlobeNewswire
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors
Via Benzinga
Topics Government
Atai Life Sciences Stock Soars To 3-Month High As Depression Study Yields Promising Results: Retail Bulls Cheer
Via Stocktwits
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
From atai Life Sciences
Via GlobeNewswire
atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression
From atai Life Sciences
Via GlobeNewswire

Frequently Asked Questions

Is ATAI Life Sciences N.V. - Common Shares publicly traded?
Yes, ATAI Life Sciences N.V. - Common Shares is publicly traded.
What exchange does ATAI Life Sciences N.V. - Common Shares trade on?
ATAI Life Sciences N.V. - Common Shares trades on the Nasdaq Stock Market
What is the ticker symbol for ATAI Life Sciences N.V. - Common Shares?
The ticker symbol for ATAI Life Sciences N.V. - Common Shares is ATAI on the Nasdaq Stock Market
What is the current price of ATAI Life Sciences N.V. - Common Shares?
The current price of ATAI Life Sciences N.V. - Common Shares is 3.835
When was ATAI Life Sciences N.V. - Common Shares last traded?
The last trade of ATAI Life Sciences N.V. - Common Shares was at 07/24/25 12:25 PM ET
What is the market capitalization of ATAI Life Sciences N.V. - Common Shares?
The market capitalization of ATAI Life Sciences N.V. - Common Shares is 636.65M
How many shares of ATAI Life Sciences N.V. - Common Shares are outstanding?
ATAI Life Sciences N.V. - Common Shares has 637M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.